Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK2 | Q9NRA0 | 4/20 | 0.50 |
| ▸ | CNR1 | P21554 | 6/20 | 0.49 |
| ▸ | CNR2 | P34972 | 5/20 | 0.49 |
| ▸ | ACHE | P22303 | 3/20 | 0.49 |
| ▸ | GYS1 | P13807 | 1/20 | 0.43 |
| ▸ | SPHK1 | Q9NYA1 | 3/20 | 0.40 |
| ▸ | BCHE | P06276 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6764408 | 0.81 | CNR2 (0.65) | CNR1CNR2ACHEBCHERAB9A | |
| SCHEMBL6761965 | 0.80 | CNR2 (0.54) | CNR1CNR2ACHEBCHERAB9A | |
| SCHEMBL6767172 | 0.76 | CNR2 (0.68) | CNR1CNR2ACHEBCHERAB9A | |
| SCHEMBL6767192 | 0.76 | CNR2 (0.51) | CNR1CNR2ACHEPOLB | |
| SCHEMBL6763450 | 0.76 | CNR2 (0.58) | CNR1CNR2ACHEBCHERAB9A | |
| SCHEMBL6766646 | 0.70 | KDM4E (0.54) | CNR1CNR2ACHEBCHERAB9A | |
| SCHEMBL8007567 | 0.68 | CNR2 (0.68) | CNR1CNR2ACHERAB9APOLB | |
| SCHEMBL16341674 | 0.68 | PTGER4 (0.48) | SPHK2CNR1CNR2POLB | |
| SCHEMBL9917454 | 0.66 | HRH3 (0.49) | SPHK2CNR1CNR2ACHESPHK1 | |
| SCHEMBL9917446 | 0.66 | HRH3 (0.49) | SPHK2CNR1CNR2ACHESPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040048866-A1 | Indazole derivatives that are activators of soluble guanylate cyclase | ABBOTT LABORATORIES | 2004-03-11 | — | — | US | claimed |
| US-20040048866-A1 | Indazole derivatives that are activators of soluble guanylate cyclase | ABBOTT LABORATORIES | 2004-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048866-A1 | Indazole derivatives that are activators of soluble guanylate cyclase | GUCY1B1, GUCY1A1, GUCY1A2 | SPHK2 1422/4885CNR1 1179/4885CNR2 1561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.